Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective.
Blagden SP, Yu LM, Ellis S, Hughes H, Shaaban A, Fennelly-Barnwell J, Lythgoe MP, Cooper AM, Maignen FM, Buckland SW, Kearns PR, Brown LC; Experimental Cancer Medicine Centres (ECMC) CID trials working group. Blagden SP, et al. Br J Cancer. 2023 Feb;128(3):474-477. doi: 10.1038/s41416-022-02051-7. Epub 2022 Nov 24. Br J Cancer. 2023. PMID: 36434156 Free PMC article.
Controversies around the function of LARP1.
Berman AJ, Thoreen CC, Dedeic Z, Chettle J, Roux PP, Blagden SP. Berman AJ, et al. Among authors: blagden sp. RNA Biol. 2021 Feb;18(2):207-217. doi: 10.1080/15476286.2020.1733787. Epub 2020 Apr 1. RNA Biol. 2021. PMID: 32233986 Free PMC article. Review.
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies.
Gungor H, Saleem A, Babar S, Dina R, El-Bahrawy MA, Curry E, Rama N, Chen M, Pickford E, Agarwal R, Blagden S, Carme S, Salinas C, Madison S, Krachey E, Santiago-Walker A, Smith DA, Morris SR, Stronach EA, Gabra H. Gungor H, et al. J Nucl Med. 2015 Dec;56(12):1828-35. doi: 10.2967/jnumed.115.156505. Epub 2015 Oct 1. J Nucl Med. 2015. PMID: 26429956 Free article. Clinical Trial.
Drugging cell cycle kinases in cancer therapy.
Blagden S, de Bono J. Blagden S, et al. Curr Drug Targets. 2005 May;6(3):325-35. doi: 10.2174/1389450053765824. Curr Drug Targets. 2005. PMID: 15857291 Review.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor-initiating cells.
Artibani M, Masuda K, Hu Z, Rauher PC, Mallett G, Wietek N, Morotti M, Chong K, KaramiNejadRanjbar M, Zois CE, Dhar S, El-Sahhar S, Campo L, Blagden SP, Damato S, Pathiraja PN, Nicum S, Gleeson F, Laios A, Alsaadi A, Santana Gonzalez L, Motohara T, Albukhari A, Lu Z, Bast RC Jr, Harris AL, Ejsing CS, Klemm RW, Yau C, Sauka-Spengler T, Ahmed AA. Artibani M, et al. Among authors: blagden sp. JCI Insight. 2021 Jun 8;6(11):e147929. doi: 10.1172/jci.insight.147929. JCI Insight. 2021. PMID: 33945502 Free PMC article.
Docetaxel in the management of ovarian cancer.
Blagden SP, Kaye SB. Blagden SP, et al. Expert Rev Anticancer Ther. 2005 Apr;5(2):203-14. doi: 10.1586/14737140.5.2.203. Expert Rev Anticancer Ther. 2005. PMID: 15877518 Review.
89 results